A double-blind randomized controlled trial investigated the effects of doxycycline on systemic inflammatory markers (cytokines and C-reactive protein) and neutrophil-specific markers, including MPO in the sputum of patients with stable chronic obstructive pulmonary disease (COPD) [170]. Here, MPO is linked to chronic obstructive pulmonary disease.